A Phase II Study of Avelumab Immunotherapy in Patients with Recurrent or Persistent Osteosarcoma (Bone Cancer)

Full Title

A Phase II Trial of Avelumab, a Fully Human Antibody That Targets Cells Expressing PD-L1 in Patients with Recurrent or Progressive Osteosarcoma

Purpose

The purpose of this study is to evaluate the safety and effectiveness of the immunotherapy drug avelumab in adolescents and adults with osteosarcoma (bone cancer) that has come back or continued to grow despite therapy. Avelumab is an antibody that works by blocking a protein on tumor cells called PD-L1. Tumor cells make PD-L1 to help them evade being detected by the immune system. By blocking this protein, avelumab may improve the ability of the immune system to find and destroy a cancer.

Avelumab is already used to treat Merkel cell cancer and urothelial cancer. Its use in this study is investigational. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have osteosarcoma that has come back or continued to grow despite treatment.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • This study is for patients who are at least 12 years old and no older than 49.

For more information and to inquire about eligibility for this study, please contact Dr. Filemon Dela Cruz at 212-639-6057.

Protocol

17-494

Phase

II

Disease Status

Relapsed or Refractory

Investigator